Nanomedicine News RSS Feed - Nanomedicine

Matinas BioPharma Announces Aquarius BioTechnologies Acquisition

Matinas BioPharma Announces Aquarius BioTechnologies Acquisition

Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company"), a clinical-stage biopharmaceutical company focused on the development and commercialization of lipid-based prescription therapeutics for the treatment of metabolic and cardiovascular conditions and the treatment of infectious diseases, announced today that it has acquired all of the outstanding stock of Aquarius BioTechnologies Inc. (Aquarius), an innovative bio-delivery drug discovery company with a novel and proprietary lipid-crystal nano-particle cochleate formulation technology platform. [More]
Proteins and Carbohydrates can be Conjugated to Nanoparticles

Proteins and Carbohydrates can be Conjugated to Nanoparticles

When University of Maryland Professors Philip DeShong and Daniel Stein began tagging soap bubbles with biomolecules, they had no idea this technology would one day be poised to change the way drugs and vaccines fight against bacteria, viruses and cancer. [More]
Synthetic, Safe Form of Ebola RNA to be Inserted in Plant Virus Nanoparticle for Early Detection

Synthetic, Safe Form of Ebola RNA to be Inserted in Plant Virus Nanoparticle for Early Detection

Health care workers must diagnose and isolate Ebola victims at an early stage to have a chance to save them and prevent the virus from spreading. But the most sensitive and quickest diagnostic test produces a small percentage of false negative results that undermine efforts to control the deadly agent. [More]
Micromotors Fueled By Stomach Acid Deliver More Gold Nanoparticles

Micromotors Fueled By Stomach Acid Deliver More Gold Nanoparticles

Researchers at the University of California, San Diego have shown that a micromotor fueled by stomach acid can take a bubble-powered ride inside a mouse. These tiny motors, each about one-fifth the width of a human hair, may someday offer a safer and more efficient way to deliver drugs or diagnose tumors. [More]
New Report on Global Gold Nanoparticles Market

New Report on Global Gold Nanoparticles Market

Global gold nanoparticles market is expected to reach USD 4.86 billion by 2020, according to a new study by Grand View Research, Inc. Medical & dentistry was the largest end-use segment for the gold nanoparticles and accounted for over 50% of total demand in 2013. [More]
MagForce Holds Pre-IDE Meeting with FDA on NanoTherm Prostate Cancer Therapy Pre-Submission

MagForce Holds Pre-IDE Meeting with FDA on NanoTherm Prostate Cancer Therapy Pre-Submission

MagForce AG (Frankfurt, Entry Standard, XETRA: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, together with its subsidiary MagForce USA, Inc. today announced that an in-person meeting was held with the U.S. Food and Drug Administration's (FDA) Center for Devices and Radiological Health to discuss FDA's response to MagForce's NanoTherm(TM) Prostate Cancer Therapy Pre-Submission of November, 2014. [More]
Nucleic Acid Therapeutics Reports Cell-Penetrating Peptide Nanoparticles Delivery

Nucleic Acid Therapeutics Reports Cell-Penetrating Peptide Nanoparticles Delivery

Therapeutic oligonucleotide analogs represent a new and promising family of drugs that act on nucleic acid targets such as RNA or DNA; however, their effectiveness has been limited due to difficulty crossing the cell membrane. [More]
Researchers Discover Unknown Way for RAS Protein to Find Proper Place in Cells

Researchers Discover Unknown Way for RAS Protein to Find Proper Place in Cells

Three of the four most fatal cancers are caused by a protein known as Ras; either because it mutates or simply because it ends up in the wrong place at the wrong time. Ras has proven an elusive target for scientist trying to cure the deadly diseases. Now a group from the Department of Chemistry, University of Copenhagen have discovered an unknown way for RAS to find its proper place in the cell. Their discovery may lead to completely novel approaches to curing cancer. [More]
Attaching Epirubicin to Nanodiamonds Effectively Eliminates Chemoresistant Cancer Stem Cells

Attaching Epirubicin to Nanodiamonds Effectively Eliminates Chemoresistant Cancer Stem Cells

A study led by the National University of Singapore (NUS) found that attaching chemotherapy drug Epirubicin to nanodiamonds effectively eliminates chemoresistant cancer stem cells. The findings were first published online in ACS Nano, the official journal of the American Chemical Society, in December 2014. [More]
BIND Therapeutics Acquires Additional Funding to Accelerate Growth of Accurin

BIND Therapeutics Acquires Additional Funding to Accelerate Growth of Accurin

BIND Therapeutics, Inc., a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, announced today that it has entered into an amendment of its existing credit facility from Hercules Technology III, L.P., an affiliate of Hercules Technology Growth Capital. Under the amendment, the company borrowed an additional $15 million in growth capital, less the repayment of the outstanding balance on BIND’s existing term loan facility of approximately $3 million. [More]